Kareus partners with Quintiles to get conjugate NCEs into clinic
This article was originally published in Scrip
Kareus Therapeutics, a Switzerland-based biotech company,has entered a strategic alliance with the CRO firm Quintiles to advance two of its preclinical programmes through to clinical trials.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.